Study of golgi protein-7 levels associated cirrhosis in patients with infections hepatitis B virus

Jaafar Ahmed Abdulmunem Baqr AL-sham; Huda Jameel Baker AL-Khilkhali

doi:10.53730/ijhs.v6nS5.10329

Authors

Jaafar Ahmed Abdulmunem Baqr AL-sham Faculty of Science, University of Kufa, Iraq
Huda Jameel Baker AL-Khilkhali Faculty of Science, University of Kufa, Iraq

Keywords:

Hepatitis B virus, Golgi protein73, Cirrhosis, HCC, ELISA

Abstract

Background/Aims: Infection with the hepatitis B virus (HBV) is a major health concern that can lead to liver failure. The hepatitis B virus (HBV) infects humans in both acute and chronic forms. The transmission of this infectious illness is caused by several risk factors. The goal of this study was to look at the epidemiology and risk factors of HBV infection. HBV infection is associated with cirrhosis and/or hepatocellular cancer (HCC). Golgi protein 73(GP73) in human serum is a useful biomarker in the evaluation of hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) by hepatitis B virus (HBV). The purpose of this study was to evaluate the serum GP73 level's ability to predict HBV infection caused by cirrhosis and/or HCC. Methods: In serum samples, GP73 levels were determined using an enzyme-linked immunosorbent assay (ELISA). This study looked at the underlying function of HBV-induced GP73 in controlling cirrhosis and/or HCC development. ELISA was used to assess hepatitis B surface Antigen (HBsAg) and GP73 expression in HBV-related to cirrhosis and/or hepatocellular cancer (HCC). Results: This study included a total of 35 patients with HBsAg by ELISA technique and 18 persons as control group negative to (HBsAg, anti-HBc-Ab, anti-HCV-Ab, HIV).

Downloads

Download data is not yet available.

References

A. Arzumanyan, H.M. Reis, and M.A. Feitelson, Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nature reviews. Cancer 13 (2013) 123-35.

A. Schweitzer, J. Horn, R.T. Mikolajczyk, G. Krause, and J.J. Ott, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet (London, England) 386(2015)1546-55.

Abdul-Hussian, I.F. (2013). Epidemiological Study of Viral Hepatitis Types B and C in Babylon Province. M.Sc. thesis. College of Medicine.University of Babylon.1-114.

ABUSAIBA, T. H. H. (2020). Prevalence of hepatitis virus B and C in patients in Al Najaf Governorate, Iraq. International Journal of Pharmaceutical Research, 12(3), 1297-1303.‏

Atilla, A., Taşkın, M. H., Kazak, Z., Aydın, S., & Kılıç, S. S. (2022). GP73 level in patients with chronic hepatitis B: Relationship with liver biopsy, levels of ALT, AST and HBV DNA. Indian Journal of Pathology and Microbiology, 65(1), 55.‏

B. Rehermann, and M. Nascimbeni, Immunology of hepatitis B virus and hepatitis C virus infection. Nature reviews. Immunology 5 (2005) 215-29.

Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produce marker for hepatocellular carcinoma. Traffic 2007;8:1415-23.

Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA. 2005;102(3):779–84.

C. Trépo, H.L. Chan, and A. Lok, Hepatitis B virus infection. Lancet (London, England) 384 (2014) 2053-63.

Cao Z, Li Z, Wang Y, Liu Y, Mo R, Ren P, et al. Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection. J Viral Hepat 2017;24(Suppl 1):57-65.

El-Baky, A., Reham, M., Hetta, H. F., Koneru, G., Ammar, M., Shafik, E. A., ... & Fathy, M. (2020). Impact of interleukin IL-6 rs-1474347 and IL-10 rs-1800896 genetic polymorphisms on the susceptibility of HCV-infected Egyptian patients to hepatocellular carcinoma. Immunologic Research, 68(3), 118-125.‏

European Association for the Study of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.

G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato, Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004) S35-50.

Iftikhar R, Kladney RD, Havlioglu N, et al. Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 2004;99:1087–1095.

J Hepatol (2017). Clinical Practice Guidelines on the management of hepatitis B virus infection.;67:370-98.

K. Jiang, W. Li, S. Shang, L. Sun, K. Guo, S. Zhang, and Y. Liu, Aberrant expression of Golgi protein 73 is indicative of a poor outcome in hepatocellular carcinoma. Oncology Reports 35 (2016) 2141-50.

Ke, M. Y., Wu, X. N., Zhang, Y., Wang, S., Lv, Y., & Dong, J. (2019). Serum GP73 predicts post hepatectomy outcomes in patients with hepatocellular carcinoma. Journal of translational medicine, 17(1), 1-10.‏

Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315–1341.

L. Hu, W. Yao, F. Wang, X. Rong, and T. Peng, GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion. PloS one 9 (2014) e90553.

Lai, Y. R., Chang, Y. L., Lee, C. H., Tsai, T. H., Huang, K. H., & Lee, C. Y. (2022). Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study. Cancers, 14(3), 583.

Liu X, Wan X, Li Z, Lin C, Zhan Y, Lu X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med 2011;49:1311-6.

Liu, L., Huang, Y., Fu, Y., Rao, J., Zeng, F., Ji, M., ... & Liu, Z. (2022). Hepatitis B Virus Promotes Hepatocellular Carcinoma Development by Activating GP73 to Repress the Innate Immune Response.‏

M.A. Sells, M.L. Chen, and G. Acs, Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proceedings of the National Academy of Sciences of the United States of America 84 (1987) 1005-9.

M.F. Yuen, D.S. Chen, G.M. Dusheiko, H.L.A. Janssen, D.T.Y. Lau, S.A. Locarnini, M.G. Peters, and C.L. Lai, Hepatitis B virus infection. Nature reviews. Disease primers 4 (2018) 18035.

Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59:1687–1693.

Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52:594–604.

Qiao Y, Chen J, Li X, Wei H, Xiao F, Chang L, Zhang R, Hao X, Wei H. Serum gp73 is also a biomarker for diagnosing cirrhosis in a population with chronic HBV infection. Clin Biochem. 2014;47(16–17):216–22.

R.D. Kladney, G.A. Bulla, L. Guo, A.L. Mason, A.E. Tollefson, D.J. Simon, Z. Koutoubia, and C.J. Fimmel, GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 249 (2000) 53-65.

R.D. Kladney, X. Cui, G.A. Bulla, E.M. Brunt, and C.J. Fimmel, Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology (Baltimore, Md.) 35 (2002) 1431- 1440.

Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, et al. Golgi phosphoprotein 2 (GOLPH 2) expression in liver tumours and its value as a serum marker in hepatocellular carcinomas. Hepatology 2009;49:1602-9.

Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017–1044.

Sun Y, Yang H, Mao Y, et al. Increased Golgi protein 73 expressions in hepatocellular carcinoma tissue correlates with tumour aggression but not survival. J Gastroenterol Hepatol. 2011;26:1207–1212.

V.T. Nguyen, M.G. Law, and G.J. Dore, Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. Journal of viral hepatitis 16 (2009) 453-63.

W. Sai, L. Wang, W. Zheng, J. Yang, L. Pan, Y. Cai, L. Qiu, H. Zhang, W. Wu, and D. Yao, Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis. Hepatitis monthly 15 (2015) e32918.

Wang, H., Men, P., Xiao, Y., Gao, P., Lv, M., Yuan, Q., ... & Wu, J. (2019). Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC infectious diseases, 19(1),110.‏

World Health Organization: Hepatitis B Factsheet 204. http:// www.who.int/mediacentre/factsheets/fs204/en/. Updated July 2014.

Wright LM, Huster D, Lutsenko S, et al. Hepatocyte GP73 expression in Wilson disease. J Hepatol. 2009;51:557–564.

Khidoyatova, M. R., Kayumov, U. K., Inoyatova, F. K., Fozilov, K. G., Khamidullaeva, G. A., & Eshpulatov, A. S. (2022). Clinical status of patients with coronary artery disease post COVID-19. International Journal of Health & Medical Sciences, 5(1), 137-144. https://doi.org/10.21744/ijhms.v5n1.1858

Xu Z, Liu L, Pan X, et al. (2015). Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease. Medicine.;94:e659.

Xu Z, Pan X, Wei K, Ding H, Wei M, Yang H, et al. Serum Golgi protein 73 levels and liver pathological grading in cases of chronic hepatitis B. Mol Med Rep 2015; 11:2644-52.

Xu Z, Shen J, Pan X, Wei M, Liu L, Wei K, et al. Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection. J Med Virol 2018;90:1053-62.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949

Xu, Z., Liu, L., Pan, X., Wei, K., Wei, M., Liu, L., ... & Liu, Q. (2015). Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease. Medicine, 94.

Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, et al. AFP, AFP- L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010;45:1272-82.